Which of the following are pathogenetic mechanisms in systemic lupus erythematosus (SLE): impaired clearance of apoptotic cells, B‑lymphocyte activation, production of autoantibodies against cyclic citrullinated peptide (CCP), association with HLA‑B27, or complement activation?

Pathogenetic Mechanisms in Systemic Lupus Erythematosus

The correct pathogenetic mechanisms in SLE are: (a) impaired clearance of apoptotic cells, (b) B-lymphocyte activation, and (e) complement activation. Anti-CCP antibodies and HLA-B27 are NOT associated with SLE pathogenesis.

Mechanisms Confirmed in SLE

Impaired Clearance of Apoptotic Cells (Option a - CORRECT)

Defective clearance of dying cells is a fundamental pathogenic mechanism in SLE 1, 2. This process involves multiple defects:

• Intrinsic macrophage dysfunction: Macrophages differentiated from SLE patients' CD34+ stem cells demonstrate reduced phagocytic capability, with heterogeneous clearance defects varying between patients 1
• Accumulation of apoptotic material: Unusually large amounts of apoptotic cells accumulate in SLE tissues, particularly in germinal centers of lymph nodes with significantly reduced tingible body macrophages 1, 2
• Secondary necrosis: Failure of early-phase clearance leads to secondary necrotic status, releasing danger signals and exposing modified autoantigens that trigger autoimmune reactions 1, 3
• Complement and opsonization defects: Deficiencies in C1q, DNaseI, and other serum factors impair efficient opsonization and uptake of apoptotic cells 2, 4

B-Lymphocyte Activation (Option b - CORRECT)

B cell hyperactivity is a hallmark pathogenic feature of SLE 5. The mechanisms include:

• Autoantibody production: B cells produce autoantibodies directed against nuclear components, present in virtually all SLE patients 6, 5
• Abnormal B cell signaling: Dysregulation in B cell signaling pathways and cytokine regulation drives autoreactive responses 5
• Clonal expansion: Autoreactive lymphocytes undergo clonal expansion, generating memory B cells and plasma cells that sustain autoantibody production 4
• Loss of tolerance: Both T and B lymphocytes lose tolerance, potentially through failure of methylation of vital genes 7

Complement Activation (Option e - CORRECT)

Complement has a dual pathogenic role in SLE 8, 9:

• Complement deficiency predisposes to SLE: Monogenic defects in early complement components (C1q, C1s, C1r, C2, C4) lead to severe lupus development 9
• Defective immune complex clearance: Early complement component defects impair clearing of immune complexes and apoptotic debris 9, 7
• Complement-mediated tissue damage: Excess complement activation contributes to organ damage, particularly in lupus nephritis through immune complex deposition and microvascular injury 4
• Complement dysregulation: The disease itself is characterized by aberrant immune responses and complement dysregulation 8

Mechanisms NOT Associated with SLE

Anti-CCP Antibodies (Option c - INCORRECT)

Autoantibodies against cyclic citrullinated peptide (CCP) are specific for rheumatoid arthritis, not SLE 10. Anti-CCP antibodies are established diagnostic and prognostic biomarkers for rheumatoid arthritis but have no role in SLE pathogenesis. SLE is characterized by antinuclear antibodies and anti-dsDNA antibodies, not anti-CCP 6.

HLA-B27 Association (Option d - INCORRECT)

HLA-B27 is the diagnostic marker for seronegative spondyloarthritis, particularly axial spondyloarthritis, not SLE 10. There is no established association between HLA-B27 and SLE pathogenesis. SLE involves different genetic susceptibility factors related to immune regulation and interferon pathways 3, 11.

Integrated Pathogenic Model

The pathogenesis of SLE represents a self-reinforcing network 3, 11:

1. Defective apoptotic clearance → increased availability of immunogenic nucleic acids
2. Nucleic acid sensing → activation of pattern recognition receptors (TLRs 7 and 9)
3. Type I interferon production → chronic immune activation
4. B cell hyperactivity → autoantibody production and immune complex formation
5. Complement activation → tissue damage and further inflammation
6. Metabolic reprogramming → sustained autoreactive immune circuits

Common Pitfall: Confusing disease-specific autoantibodies—anti-CCP is for rheumatoid arthritis, anti-dsDNA is for SLE. Similarly, HLA-B27 associates with spondyloarthropathies, not lupus.